Federal and State Pharmacy Regulations and Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the US-Reference-Cited by-同舟云学术

Federal and State Pharmacy Regulations and Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the US

Published:2022-08-26 Issue:8 Volume:3 Page:e222839
ISSN:2689-0186
Container-title:JAMA Health Forum
language:en
Short-container-title:JAMA Health Forum

Author:

Qato Dima M.¹²,Watanabe Jonathan H.³,Clark Kelly J.⁴

Affiliation:

1. Program on Medicines and Public Health, School of Pharmacy, Department of Clinical Pharmacy, University of Southern California, Los Angeles

2. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles

3. Department of Clinical Pharmacy Practice, University of California, Irvine School of Pharmacy & Pharmaceutical Sciences, Irvine

4. Addiction Crisis Solutions, Louisville, Kentucky

Abstract

This Viewpoint describes federal and state pharmacy regulations that may create barriers to buprenorphine access at pharmacies and suggests policy changes to address those barriers.

Publisher

American Medical Association (AMA)

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://jamanetwork.com/journals/jama-health-forum/articlepdf/2795746/qato_2022_vp_220024_1664828913.44061.pdf

Reference10 articles.

2. Pharmacists’ readiness to provide naloxone in community pharmacies in West Virginia.;Thornton;J Am Pharm Assoc (2003),2017

3. Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. 2021. Accessed June 5, 2022. https://www.govinfo.gov/content/pkg/FR-2021-04-28/pdf/2021-08961.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacy-based expansion of buprenorphine access;Journal of Substance Use and Addiction Treatment;2024-02

2. Disparities in access to opioid treatment programs and buprenorphine providers by race and ethnicity in the contiguous U.S.;Journal of Substance Use and Addiction Treatment;2024-01

3. The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice;Journal of the American Pharmacists Association;2023-07

4. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility;Journal of the American Pharmacists Association;2023-07

5. Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US;JAMA Network Open;2023-05-26